MEREO BIOPHARMA (MREO)
(Real Time Quote from BATS)
$2.77 USD
-0.04 (-1.42%)
Updated Apr 26, 2024 12:10 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for MEREO BIOPHARMA falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 10 | 0 | 50 | 0 | 0 |
Cost Of Goods | 3 | -1 | 25 | 0 | 0 |
Gross Profit | 7 | 1 | 26 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 36 | 55 | 54 | 48 | 50 |
Income After Depreciation & Amortization | -28 | -54 | -29 | -48 | -50 |
Non-Operating Income | 1 | 13 | 54 | -157 | 2 |
Interest Expense | 3 | 4 | 6 | 8 | 4 |
Pretax Income | -30 | -45 | 20 | -214 | -53 |
Income Taxes | -1 | -2 | 2 | -4 | -8 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -42 | 18 | -210 | -44 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -42 | 18 | -210 | -44 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -53 | -28 | -46 | -48 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 2 | 2 |
Income After Depreciation & Amortization | -28 | -54 | -29 | -48 | -50 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 131.89 | 120.08 | 111.06 | 68.18 | 17.89 |
Diluted EPS Before Non-Recurring Items | -0.20 | -0.37 | -0.34 | -3.08 | -2.49 |
Diluted Net EPS (GAAP) | -0.20 | -0.37 | -0.34 | -3.10 | -2.49 |
Fiscal Year end for MEREO BIOPHARMA falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |